Optimizing management of ruxolitinib in patients with myelofibrosis: The need for individualized dosing

Ruben A. Mesa, Jorge Cortes

Research output: Contribution to journalReview article

Abstract

Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and burdensome symptoms. Phase III clinical studies have shown that ruxolitinib reduces splenomegaly and alleviates MF-related symptoms, with concomitant improvements in quality of life measures, for the overwhelming majority of treated patients. In addition, ruxolitinib provided an overall survival advantage as compared with either placebo or what was previously considered best available therapy in the two phase III studies. The most common adverse events with ruxolitinib treatment include dose-dependent anemia and thrombocytopenia, which are expected based on its mechanism of action. Experience from the phase III studies shows that these hematologic events can be managed effectively with dose modifications, temporary treatment interruptions, as well as red blood cell transfusions in the case of anemia and, importantly, are rarely cause for permanent treatment discontinuation. This review summarizes data supporting appropriate individualized patient management through careful monitoring of blood counts and dose titration as needed in order to maximize treatment benefit.

Original languageEnglish (US)
Article number79
JournalJournal of Hematology and Oncology
Volume6
Issue number1
DOIs
StatePublished - Oct 25 2013
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Splenomegaly
Anemia
Therapeutics
Erythrocyte Transfusion
Thrombocytopenia
Placebos
Quality of Life
INCB018424
Survival
Neoplasms

Keywords

  • Anemia
  • COMFORT-I
  • Dosing
  • JAK inhibitor
  • Myelofibrosis
  • Ruxolitinib
  • Thrombocytopenia

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Oncology
  • Cancer Research

Cite this

Optimizing management of ruxolitinib in patients with myelofibrosis : The need for individualized dosing. / Mesa, Ruben A.; Cortes, Jorge.

In: Journal of Hematology and Oncology, Vol. 6, No. 1, 79, 25.10.2013.

Research output: Contribution to journalReview article

@article{9f2742a39ce646b3b467b5bcbf9e886c,
title = "Optimizing management of ruxolitinib in patients with myelofibrosis: The need for individualized dosing",
abstract = "Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and burdensome symptoms. Phase III clinical studies have shown that ruxolitinib reduces splenomegaly and alleviates MF-related symptoms, with concomitant improvements in quality of life measures, for the overwhelming majority of treated patients. In addition, ruxolitinib provided an overall survival advantage as compared with either placebo or what was previously considered best available therapy in the two phase III studies. The most common adverse events with ruxolitinib treatment include dose-dependent anemia and thrombocytopenia, which are expected based on its mechanism of action. Experience from the phase III studies shows that these hematologic events can be managed effectively with dose modifications, temporary treatment interruptions, as well as red blood cell transfusions in the case of anemia and, importantly, are rarely cause for permanent treatment discontinuation. This review summarizes data supporting appropriate individualized patient management through careful monitoring of blood counts and dose titration as needed in order to maximize treatment benefit.",
keywords = "Anemia, COMFORT-I, Dosing, JAK inhibitor, Myelofibrosis, Ruxolitinib, Thrombocytopenia",
author = "Mesa, {Ruben A.} and Jorge Cortes",
year = "2013",
month = "10",
day = "25",
doi = "10.1186/1756-8722-6-79",
language = "English (US)",
volume = "6",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Optimizing management of ruxolitinib in patients with myelofibrosis

T2 - The need for individualized dosing

AU - Mesa, Ruben A.

AU - Cortes, Jorge

PY - 2013/10/25

Y1 - 2013/10/25

N2 - Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and burdensome symptoms. Phase III clinical studies have shown that ruxolitinib reduces splenomegaly and alleviates MF-related symptoms, with concomitant improvements in quality of life measures, for the overwhelming majority of treated patients. In addition, ruxolitinib provided an overall survival advantage as compared with either placebo or what was previously considered best available therapy in the two phase III studies. The most common adverse events with ruxolitinib treatment include dose-dependent anemia and thrombocytopenia, which are expected based on its mechanism of action. Experience from the phase III studies shows that these hematologic events can be managed effectively with dose modifications, temporary treatment interruptions, as well as red blood cell transfusions in the case of anemia and, importantly, are rarely cause for permanent treatment discontinuation. This review summarizes data supporting appropriate individualized patient management through careful monitoring of blood counts and dose titration as needed in order to maximize treatment benefit.

AB - Ruxolitinib, an oral JAK1 and JAK2 inhibitor, is approved in the US for patients with intermediate or high-risk myelofibrosis (MF), a chronic neoplasm associated with aberrant myeloproliferation, progressive bone marrow fibrosis, splenomegaly, and burdensome symptoms. Phase III clinical studies have shown that ruxolitinib reduces splenomegaly and alleviates MF-related symptoms, with concomitant improvements in quality of life measures, for the overwhelming majority of treated patients. In addition, ruxolitinib provided an overall survival advantage as compared with either placebo or what was previously considered best available therapy in the two phase III studies. The most common adverse events with ruxolitinib treatment include dose-dependent anemia and thrombocytopenia, which are expected based on its mechanism of action. Experience from the phase III studies shows that these hematologic events can be managed effectively with dose modifications, temporary treatment interruptions, as well as red blood cell transfusions in the case of anemia and, importantly, are rarely cause for permanent treatment discontinuation. This review summarizes data supporting appropriate individualized patient management through careful monitoring of blood counts and dose titration as needed in order to maximize treatment benefit.

KW - Anemia

KW - COMFORT-I

KW - Dosing

KW - JAK inhibitor

KW - Myelofibrosis

KW - Ruxolitinib

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84886871385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886871385&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-6-79

DO - 10.1186/1756-8722-6-79

M3 - Review article

C2 - 24283870

AN - SCOPUS:84886871385

VL - 6

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 79

ER -